Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anti-leukotrienes for asthma.

W J Calhoun1

  • 1Asthma, Allergy, and Airway Research Center, Division of Pulmonary, Allergy, and Critical Care Medicine, Pittsburgh, PA 15213, USA. calhounwj@msx.upmc.edu

Current Opinion in Pharmacology
|November 20, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current prospective of aldose reductase inhibition in the therapy of allergic airway inflammation in asthma.

Current molecular medicine·2011
Same author

Can anti-IgE therapy prevent airway remodeling in allergic asthma?

Allergy·2011
Same author

Predicting worsening asthma control following the common cold.

The European respiratory journal·2008
Same author

Asthma entities.

Drugs of today (Barcelona, Spain : 1998)·2003
Same author

Increased nitric oxide production by airway cells of sensitized and challenged IL-10 knockout mice.

Journal of leukocyte biology·2001
Same author

Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone.

American journal of respiratory and critical care medicine·2001
Same journal

Targeting the ischemic cascade: Review on approved and investigational stroke therapies.

Current opinion in pharmacology·2026
Same journal

Senotherapeutic strategies for ovarian aging: Mechanistic insights and translational perspectives.

Current opinion in pharmacology·2026
Same journal

Chrono-immunotherapy in precision oncology: Circadian control of the tumor microenvironment and time-of-day optimization of immune checkpoint blockade.

Current opinion in pharmacology·2026
Same journal

Methotrexate: Integrating molecular pharmacology, systems toxicology, and precision rescue strategies.

Current opinion in pharmacology·2026
Same journal

Acupuncture and non-invasive neuromodulation-induced neuro-endocrine-immune changes associated with the amelioration of depression-like behaviors: A systematic review of animal studies.

Current opinion in pharmacology·2026
Same journal

Alopecia areata: Mechanisms, targeted therapies, and translational challenges.

Current opinion in pharmacology·2026
See all related articles

Recent cysteinyl leukotriene research advances include genetic control, inflammation mechanisms, and broader clinical use of leukotriene modifiers for asthma and allergic diseases.

Area of Science:

  • Immunology and molecular biology
  • Pharmacology and therapeutics

Background:

  • Cysteinyl leukotrienes play a key role in inflammatory and allergic diseases.
  • Understanding their genetic regulation and inflammatory mechanisms is crucial for developing effective therapies.

Purpose of the Study:

  • To review recent significant advances in cysteinyl leukotriene research.
  • To highlight progress in understanding genetic control and inflammatory pathways.
  • To discuss the expanded clinical applications of leukotriene modifiers.

Main Methods:

  • Literature review of recent studies in cysteinyl leukotriene research.
  • Analysis of findings related to genetic alterations (promoter region, mRNA).
  • Examination of research on inflammatory mechanisms mediated by cysteinyl leukotrienes.

Related Experiment Videos

  • Assessment of clinical data supporting leukotriene modifiers in asthma and allergic diseases.

    • Main Results:

    • Advances in understanding genetic control of cysteinyl leukotriene response, including promoter and mRNA alterations.
    • Elucidation of mechanisms by which cysteinyl leukotrienes contribute to inflammation.
    • Clinical evidence supporting the broader use of leukotriene modifiers in managing asthma and allergic conditions.

    Conclusions:

    • Significant progress has been made in cysteinyl leukotriene research.
    • New insights into genetic and mechanistic aspects offer therapeutic potential.
    • Leukotriene modifiers are increasingly recognized for their role in treating asthma and allergic diseases.